ResMed (RMD) Faces A 10% Fair Value Gap As Dividend Rises 10%
ResMed (RMD) has given income focused investors fresh information to consider after it declared a quarterly dividend of $0.66 per share, a 10% increase, alongside its latest earnings and buyback update.
See our latest analysis for ResMed.
ResMed shares have recently picked up some momentum, with a 30 day share price return of 10.29% and a 90 day return of 11.10%. However, the year to date share price performance is down 8.16% and the 1 year total shareholder return has declined 19.86%, while the 3 year total shareholder return is 26.27%. This points to a stock that has rewarded longer term holders more than recent buyers.
If this mix of dividend growth and shifting sentiment has your attention, it can also be a good time to look at other healthcare focused opportunities through the 43 healthcare AI stocks
ResMed now trades around 10% below the average analyst price target and at a deeper intrinsic value discount of roughly 31%, even after the recent rebound. Is that a cautious market misread, or a fair response to FY27 risks?
Most Popular Narrative: 9.3% Undervalued
Based on the most followed ResMed narrative, a fair value of $247.93 sits above the last close of $224.84. This frames the current discount as modest rather than extreme.
Strategic investments in expanding the diagnosis and treatment funnel, including acquisitions like VirtuOx, Ectosense, and Somnoware, are improving patient flow from screening to therapy. This positions ResMed to capture a larger share of the substantial underpenetrated global sleep apnea and respiratory market and supports long term revenue growth.
Want to see how this sleep health funnel story turns into numbers? The narrative leans heavily on steady top line expansion, margin resilience, and a richer earnings multiple. The full breakdown joins these pieces into one valuation roadmap.
Result: Fair Value of $247.93 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, ResMed’s story could be tested if ventilator component constraints drag on earnings or if Philips Respironics returns and intensifies competition in 2027.
Find out about the key risks to this ResMed narrative.
Next Steps
Given the mixed mood around ResMed in this article, it makes sense to check the underlying data yourself and move quickly to shape your own view. To see what is driving current optimism from a rewards point of view, review the 4 key rewards
Looking for more ideas beyond ResMed?
If you are serious about building a stronger portfolio, do not stop with ResMed. Use focused stock lists to spot opportunities that others might miss.
- Target potential mispriced opportunities by scanning the 49 high quality undervalued stocks that combine quality fundamentals with appealing entry points.
- Strengthen your income stream by reviewing the 8 dividend fortresses and see which companies currently offer higher yields with support from their financials.
- Reduce portfolio shocks by focusing on the 85 resilient stocks with low risk scores that currently score well on resilience and balance sheet strength.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com